trending Market Intelligence /marketintelligence/en/news-insights/trending/wobi_ngn0nioYGtuMDqI-A2 content esgSubNav
In This List

Gene-therapy focused Genprex prices IPO

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Gene-therapy focused Genprex prices IPO

Genprex Inc. priced its IPO of between 2.5 million and 4.5 million shares on the Nasdaq Capital Market at $5 apiece.

The clinical stage gene therapy company — which would trade under the "GNPX" symbol will primarily use funds raised to continue developing its lung cancer drug Oncoprex which is currently in phase 2 trial.

The company expects the offering to close on Nov. 6 with Network 1 Financial Securities Inc. acting as its underwriter.